. 15. Sternberg CN de Mulder PH Schornagel JH . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC
Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer and Lisa A. Gurski
Andrew D. Zelenetz
relative dose intensity was lower for older patients as a consequence of dose reductions and delays attributable to toxicity. 15 This finding corresponded to a lower 5-year PFS compared with younger patients. In older patients, 5% of deaths were from HL
Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar
found that increased toxicity of that dose forced decreasing dose to approximately 600 mg, daily when considering the actually administered dose intensity. 43 – 45 Additionally, the French SPIRIT trial reported superior major molecular response (MMR
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla and Arun S. Singh
age on outcome is controversial; limited data have indicated that the outcome for adults is not as promising as for adolescents, 14 , 15 but other studies have shown that adults are not always treated with the same chemotherapy dose intensity as
Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler
intensity in this arm. At 12 months, MMR was observed in 62% patients with an average dose intensity of 600 to 799 mg/d, and in 38% of patients with an average dose intensity of 400 to 599 mg/d. 16 These data suggest that patients who can tolerate high
Joseph M. Pepek, Christopher G. Willett and Brian G. Czito
radiation dose by partitioning a given radiation field into multiple smaller fields of different shapes and sizes, varying the radiation dose intensity between each area. 18 This is performed with either dynamic IMRT (where collimating leaves, or blocks
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre and Gary H. Lyman
Moliterni A Zambetti M . 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study . BMJ 2005 ; 330 : 217 . 5. Lyman GH Dale DC Crawford J . Incidence and predictors of low dose-intensity in adjuvant
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria
between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older [abstract] . J Clin Oncol 2011 ; 29 ( Suppl ): Abstract 9000 . 17
Pooja Ghatalia and Elizabeth R. Plimack
Program. Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html . Accessed January 5, 2019 . 3. Sternberg CN , de Mulder PH , Schornagel JH , . Randomized phase III trial of high-dose-intensity
Ramy Sedhom, Amanda L. Blackford, Arjun Gupta, Kelly Griffiths, Janet Heussner and Michael A. Carducci
patients with advanced cancer: a cluster-randomised controlled trial . Lancet 2014 ; 383 : 1721 – 1730 . 10.1016/S0140-6736(13)62416-2 38. Sedhom R , Gupta A , MacNabb L , . The impact of palliative care dose intensity on outcomes for patients
